Pelvic lymph node status prediction in melanoma patients with inguinal lymph node metastasis

2014 ◽  
Vol 24 (5) ◽  
pp. 462-467 ◽  
Author(s):  
Sandro Pasquali ◽  
Simone Mocellin ◽  
Francesco Bigolin ◽  
Antonella Vecchiato ◽  
Maria C. Montesco ◽  
...  
2021 ◽  
Vol 10 (4) ◽  
pp. 754
Author(s):  
Rodrigo Suarez-Ibarrola ◽  
Mario Basulto-Martinez ◽  
August Sigle ◽  
Mohammad Abufaraj ◽  
Christian Gratzke ◽  
...  

We aim to review the literature for studies investigating the oncological outcomes of patients with penile cancer (PC) undergoing bilateral pelvic lymph node dissection (PLND) in the presence of inguinal lymph node metastasis (LNM) who are at risk of harboring pelvic metastasis. A search of English language literature was performed using the PubMed-MEDLINE database up to 3 December 2020 to identify articles addressing bilateral PLND in PC patients. Eight articles investigating bilateral PLND met our inclusion criteria. Patients with pelvic LNM have a dismal prognosis and, therefore, PLND has an important role in both the staging and treatment of PC patients. Ipsilateral PLND is recommended in the presence of ≥2 positive inguinal nodes and/or extranodal extension (ENE). Significant survival improvements were observed with a higher pelvic lymph node yield, in patients with pN2 disease, and in men treated with bilateral PLND as opposed to ipsilateral PLND. Nevertheless, the role of bilateral PLND for unilateral inguinal LNM remains unclear. Although the EAU guidelines state that pelvic nodal disease does not occur without ipsilateral inguinal LNM, metastatic spread from one inguinal side to the contralateral pelvic side has been reported in a number of studies. Further studies are needed to clarify the disseminative pattern of LNM, in order to establish PLND templates according to patients’ risk profiles and to investigate the benefit of performing bilateral PLND for unilateral inguinal disease.


2018 ◽  
Vol 60 (2) ◽  
pp. 151-153
Author(s):  
Mari Hioki ◽  
Akifumi Ohshita ◽  
Sachiyo Yoshida ◽  
Fuminao Kanehisa ◽  
Norito Katoh ◽  
...  

Urology ◽  
1993 ◽  
Vol 41 (3) ◽  
pp. 275-277 ◽  
Author(s):  
Kenji Nishimoto ◽  
Hiroshi Ono ◽  
Masaaki Hirayama ◽  
Yukihisa Kadomoto ◽  
Tsuguru Usui

2001 ◽  
Vol 81 (2) ◽  
pp. 324-325 ◽  
Author(s):  
Brett A. Winter-Roach ◽  
Wiebren A. Tjalma ◽  
Andrew J. Nordin ◽  
Raj Naik ◽  
Alberto de Barros Lopes ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Chengyan Zhang ◽  
Guanchao Pang ◽  
Chengxi Ma ◽  
Jingni Wu ◽  
Pingli Wang ◽  
...  

Background. Lymph node status of clinical T1 (diameter≤3 cm) lung cancer largely affects the treatment strategies in the clinic. In order to assess lymph node status before operation, we aim to develop a noninvasive predictive model using preoperative clinical information. Methods. We retrospectively reviewed 924 patients (development group) and 380 patients (validation group) of clinical T1 lung cancer. Univariate analysis followed by polytomous logistic regression was performed to estimate different risk factors of lymph node metastasis between N1 and N2 diseases. A predictive model of N2 metastasis was established with dichotomous logistic regression, externally validated and compared with previous models. Results. Consolidation size and clinical N stage based on CT were two common independent risk factors for both N1 and N2 metastases, with different odds ratios. For N2 metastasis, we identified five independent predictors by dichotomous logistic regression: peripheral location, larger consolidation size, lymph node enlargement on CT, no smoking history, and higher levels of serum CEA. The model showed good calibration and discrimination ability in the development data, with the reasonable Hosmer-Lemeshow test (p=0.839) and the area under the ROC being 0.931 (95% CI: 0.906-0.955). When externally validated, the model showed a great negative predictive value of 97.6% and the AUC of our model was better than other models. Conclusion. In this study, we analyzed risk factors for both N1 and N2 metastases and built a predictive model to evaluate possibilities of N2 metastasis of clinical T1 lung cancers before the surgery. Our model will help to select patients with low probability of N2 metastasis and assist in clinical decision to further management.


Sign in / Sign up

Export Citation Format

Share Document